RESUMEN
Wax deposition in high-wax (waxy) crude oil has been an important challenge in the oil and gas industry due to the repercussions in flow assurance during oil extraction and transportation. However, the nanotechnology has emerged as a potential solution for the optimization of conventional wax removal and/or inhibition processes due to its exceptional performance in the alteration of wax morphology and co-crystallization behavior. In this sense, this study aims to study the performance of two commercial wax inhibitor treatments (WT1 and WT2) on the wax formation and crystallization due to the addition of SiO2 nanoparticles. Differential scanning calorimetry experiments and cold finger tests were carried out to study the effect of the WT on wax appearance temperature (WAT) and the wax inhibition efficiency (WIE) in a scenario with an initial temperature difference. In the first stage, the behavior of both WT in the inhibition of wax deposition was achieved, ranging in the concentration of the WT in the waxy crude (WC) oil from 5000 to 50,000 mg·L-1. Then, NanoWT was prepared by the addition of SiO2 nanoparticles on WT1 and WT2 for concentrations between 1000 and 500 mg·L-1, and the performance of the prepared NanoWT was studied at the best concentration of WIT in the absence of nanoparticles. Finally, the role of the nanofluid concentration in wax inhibition was accomplished for the best NanoWT. Selected NanoWT with nanoparticle dosage of 100 mg·L-1 added to WC oil at 5000 mg·L-1 displays reductions in WAT and WIE of 15.3 and 71.6 for NanoWT1 and -2.2 and 42.5% for NanoWT2. In flow loop experiments for the crude oil at temperatures above (30 °C) and below (16 °C), the WAT value indicates an increase of 8.3 times the pressure drops when the crude oil is flowing at a temperature below the WAT value. Therefore, when NanoWT1 is added to the crude oil, a reduction of 31.8% was found in the pressure drop in comparison with the scenario below the WAT value, ensuring the flow assurance in the pipeline in an unfavorable environment. Based on the pressure-drop method, a reduction greater than 5% in the wax deposit thickness confirms the wax deposition inhibitory character of the designed NanoWT.
RESUMEN
Introducción. El remifentanilo en combinación con propofol provee adecuadas condiciones para la intubación orotraqueal sin relajante neuromuscular. Otros agentes inductores no han sido adecuadamente evaluados. El propósito del estudio fue evaluar las condiciones de intubación y los cambios hemodinámicos tras la inducción anestésica con remifentanilo-propofol o remifentanilo- etomidato. Métodos. En este estudio prospectivo, doble ciego y aleatorio, participaron 90 pacientes con clasificación ASA I/II. Recibieron 0,03 mg/kg de midazolam y 7 ml/kg de lactato de Ringer, y posteriormente, 3 mg/kg de remifentanilo seguidos de 1 mg/kg de lidocaína. A continuación, se distribuyeron en forma aleatoria en los siguientes grupos de pacientes: los que recibieron 2 mg/kg de propofol (grupo propofol, n=29), 0,3 mg/ kg de etomidato (grupo etomidato 3, n=31) o 0,4 mg/kg de etomidato (grupo etomidato 4, n=30). Después se realizó laringoscopia e intubación orotraqueal. Las condiciones para la intubación se evaluaron utilizando un sistema cualitativo de puntaje. Se registraron la presión arterial media y la frecuencia cardiaca previa a la inducción, posterior a la inducción, inmediatamente después de la intubación y cada minuto hasta 5 minutos después de la intubación. Resultados. Tres pacientes del grupo etomidato 3 y dos del grupo etomidato 4 no pudieron ser intubados en el primer intento. Se alcanzaron condiciones clínicamente aceptables de intubación en 100%, 74% y 80%, en los grupo propofol, etomidato 3 y etomidato 4, respectivamente (p=0,016). El descenso en la presión arterial media fue significativamente mayor en el grupo propofol comparado con el grupo etomidato 3. Conclusiones. Para la intubación orotraqueal sin relajante neuromuscular, el uso de remifentanilo-propofol es superior al de remifentanilo-etomidato, 0,3 mg/kg o 0,4 mg/kg. Con 0,3 mg/kg de etomidato se obtiene un mejor perfil hemodinámico.
Introduction: Remifentanil followed by propofol provides adequate conditions for tracheal intubation without using muscle relaxants. Other hypnotic drugs have not been thoroughly evaluated in this regard. The purpose of this study was to assess intubating conditions and cardiovascular changes after induction of anesthesia with remifentanil-propofol or. Methods: 90 ASA I/II patients were enrolled in this random, prospective, double-blind study. Subjects received 0.03 mg/kg of midazolam followed by a 7 ml/kg infusion of RingerLs lactate. After that, 3 Êg/kg of remifentanil were injected followed by lydocaine, 1 mg/kg. Then, patients received either propofol (2 mg/ kg) (Propofol Group, n= 29), or etomidate (0.3 mg/kg) (Etomidate 3 Group, n=31) or etomidate (0.4 mg/kg) (Etomidate 4 Group, n=30). Subsequent laryngoscope and intubation were performed. Intubating conditions were assessed using a quality scoring system. Mean arterial pressure and heart rates pre-induction, post-induction were recorded immediately after intubation and every 1 to 5 minutes after intubation. Results: Three patients in the etomidate 3 Group and two patients in the etomidate 4 Group were not able to beintubated in the first attempt. Clinically acceptable intubating conditions were observed in 100%, 74%, 80% in the Propofol, Etomidate 3 and etomodate 4 groups, respectively (p=0.01 6). The decrease in mean arterial pressure was significantly higher in the propofol group as compared to the etomidate 3 group (p<0.05). Conclusions: The use of lydocaine-remifentanil-propofol for tracheal intubation without muscle relaxants is superior to 0.3 or 0.4 mg/kg lydocaine-remifentanil plus etomidate. However, etomidate 0.3 mg/kg produces a better hemodynamic profile when compared to propofol.